# Fludarabine Phosphate, Melphalan, and Alemtuzumab Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed Hodgkin Lymphoma

> **NCT00907036** · PHASE2 · UNKNOWN · sponsor: **Cancer Research UK** · enrollment: 49 (estimated)

## Conditions studied

- Lymphoma

## Interventions

- **BIOLOGICAL:** alemtuzumab
- **BIOLOGICAL:** donor lymphocytes
- **DRUG:** cyclosporine
- **DRUG:** fludarabine phosphate
- **DRUG:** melphalan
- **PROCEDURE:** allogeneic hematopoietic stem cell transplantation

## Key facts

- **NCT ID:** NCT00907036
- **Lead sponsor:** Cancer Research UK
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2009-07
- **Primary completion:** 2015-07
- **Final completion:** —
- **Target enrollment:** 49 (ESTIMATED)
- **Last updated:** 2013-08-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00907036

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00907036, "Fludarabine Phosphate, Melphalan, and Alemtuzumab Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed Hodgkin Lymphoma". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT00907036. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*